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Abstract
 .  .We demonstrated previously that tissue-type plasminogen activator t-PA bound to its specific receptor t-PAR on
 .human umbilical vein endothelial cells HUVEC in suspension and that t-PAR of mol wt. 20 kDa interacted only with t-PA
  .to form 90 kDa complex Fukao, H., Hagiya, Y., Nonaka, T., Okada, K., and Matsuo, O. 1992 Biochem. Biophys. Res.
.Commun. 187, 956–962 . In the present study, 20 kDa t-PAR was purified from HUVEC and the function of the t-PAR was
investigated by analyzing its effect on plasminogen activation by t-PA. About 2.2 mg t-PAR protein was purified from cell
9  .lysate of 1.0=10 HUVEC as a single band on sodium dodecyl sulfate-polyacrylamide gel electrophoresis SDS-PAGE
 .by gel filtration with TSK-3000SW and reversed phase separation with high performance liquid chromatography HPLC .
125I-t-PA but not 125I-plasminogen specifically bound to the purified t-PAR in ligand blot assay. Plasminogen activation by
t-PA in the presence of purified t-PAR in solution was increased. Furthermore, t-PA bound to immobilized t-PAR
efficiently expressed its plasminogen activation activity. Kinetic analysis revealed that t-PA in the presence of soluble
t-PAR and t-PA bound to immobilized t-PAR exhibited 34- and 90-fold increase in plasminogen activation, respectively.
The t-PAR did not interact with anti-annexin II antibody. These findings indicate that the 20 kDa t-PAR is a novel molecule
which immobilizes t-PA and enhances its proteolytic activity on the cell surface of endothelial cells.
 .Keywords: Endothelial cell; Tissue plasminogen activator; Specific receptor; HPLC; Human umbilical vein
1. Introduction
Endothelial cells serve to regulate the fibrinolytic
system in the blood by secreting tissue-type plas-
 . w xminogen activator t-PA 1 or urokinase-type plas-
 . w xminogen activator u-PA 2 as well as type-1 plas-
 . w xminogen activator inhibitor PAI-1 3 . In addition to
these fibrinolytic factors in the solution phase, the
function of pericellular fibrinolysis has recently been
examined. PAI-1 effectively expresses its inhibitory
 . w xactivity on the extracellular matrix ECM 4 . Acti-
) Corresponding author. Fax: q81 723 662853.
vation of pericellular fibrinolysis is mediated by u-PA
 . w x w xreceptor u-PAR 5 or plasminogen receptor 6 .
PAI-1 as well as u-PAR is also expressed in carci-
w xnoma cells 7 . Among these factors, u-PAR is deeply
w x w xinvolved in tissue destruction 8 , cell invasion 9
w xand the metastasis of carcinoma cells 10 . Although
u-PAR has been demonstrated in endothelial cells
w x11 , its function remains unclear.
Since t-PA is a more potent activator of fibrinoly-
sis in the blood than u-PA, it is considered that the
 .receptor for t-PA t-PAR may immobilize t-PA on
the cell surface, so affording one of the antithrom-
botic properties to vascular endothelial cells. Recent
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studies demonstrated that purified t-PAR with mol
wt. 40 kDa from endothelial cells is identical to
w xannexin II 12 and that both t-PA and plasminogen
bind to different binding sites in the molecule, thus
exhibiting an enhancement of t-PA-dependent plas-
w xminogen activation 13 . Another study indicated that
t-PA and plasminogen bind to the common binding
site on endothelial cells, resulting in competition
between t-PA and plasminogen for the cellular bind-
w xing site 14,15 . Since u-PAR has only one ligand
u-PA in the cell surface fibrinolytic system, the exis-
tence of single authentic t-PAR on endothelial cells
which recognizes only t-PA but not other components
such as plasminogen has been expected.
By employing suspension cultures of human um-
 .bilical vein endothelial cells HUVEC which do not
produce ECM, we have demonstrated t-PAR of mol
w xwt. 20 kDa in endothelial cells 16 which specifically
interacts with t-PA by forming a complex of mol wt.
90 kDa. Further, the t-PAR was quite different from
other t-PA binding molecules such as that from the
w x w xplacenta 17 or endothelial cells 18 as regards its
molecular weight and binding ability to plasminogen.
In the present study, we purified t-PAR of mol wt. 20
kDa from HUVEC and analyzed its biological func-
tion as a modulator of plasminogen activation by
t-PA.
2. Materials and methods
2.1. Materials
Recombinant t-PA from Genentech South San
.Francisco, CA was iodinated with 125I by IODO-
 .GEN Pierce, IL . Aprotinin was obtained from
 .Mochida Tokyo . Glu-plasminogen was purified
from human plasma by Lys-Sepharose column chro-
matography followed by gel filtration with Sephadex
 .G-150. Bovine serum albumin BSA and phenyl-
 .methylsulfonyl fluoride PMSF were from Sigma
 .  .St. Louis, MO . Disuccinimidyl suberate DSS was
 .from Pierce Rockford, IL . Mouse monoclonal anti-
annexin II antibody was from Zymed Lab. Inc. San
.Francisco, CA , and two mouse monoclonal antibod-
 .ies to annexin II light chain clone LC148 and heavy
 .chain clone CP1-50-5-1 were from Affinity Re-
 .search Products Ltd. Mamhead . Non-immune IgG
was prepared from rabbit serum by protein A-Sep-
harose and aprotinin-Sepharose column chromatogra-
phy. All other chemicals were of analytical reagent
grade or the highest quality commercially available.
2.2. Cell culture
Endothelial cells were isolated from the human
umbilical cord vein according to the ordinary meth-
w xods 19 . The materials were kindly provided by Drs.
Noriyuki Suehara, Masahiro Nakayama, Keiichi
Ohzono, Sotaro Mushiake Osaka Medical Center
.and Research Institute for Maternal and Child Health ,
 . Koji Saita Saita Maternity Clinic , Yuzo Ohga Ohga
.  .Hospital , Sonosuke Kitagaki Chifune Hospital and
 .Takefumi Matsuo Awaji Hospital . The primary cells
2  .were cultured in a 75-cm flask Corning, NY in
 .RPMI-1640 Nissui, Tokyo supplemented with 20%
 .fetal calf serum Gibco, Grand Island, NY , 2 mM
glutamine and 100 ppm lilacillin Takeda Pharma-
.  7 .ceut., Osaka . Confluent cells 2.0=10 cellsrflask
were harvested and the cell pellet was frozen at
y808C until use.
2.3. Purification of t-PAR
 9 .The frozen cell pellet 1.0=10 cells was rapidly
thawed and lyzed with a lysis buffer consisting of 10
 .mM TrisrHCl pH 7.5 containing 0.5 M NaCl, 1
mM PMSF, 100 KIErml aprotinin and 1% Tween
 .80. The crude cell extract 2.5 mgrml, 200 ml was
subjected to molecular sieving with TSK-3000SW
 .21.5 mm ID=7.5 cm in a high performance liquid
 .  .chromatography HPLC system Tosoh, Tokyo , and
 .the low mol wt. protein fraction 10–50 kDa was
pooled. This fraction was further purified with a
 . reversed phase column C8 2.1 mm=30 mm Ap-
.plied Biosystems, San Jose, CA employing a linear
gradient of acetonitrile 0–70% in 0.1% trifluoro-
.acetic acid in a computer-regulated SMART system
 .Pharmacia LKB Biotechnol, Uppsala . Each peak
yielded by the elution was subjected to 125I-t-PA
binding assay on nitrocellulose membrane and SDS-
PAGErsilver staining, and the peak corresponding to
20 kDa protein with t-PA binding activity was selec-
tively obtained. The final material was lyophilized by
Speed Vac SC110 Savant Instruments Inc., Farming-
.dale, NY .
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2.4. Sodium dodecyl sulfate-polyacrylamide gel elec-
( )trophoresis SDS-PAGE
The purity of proteins was assessed by analytical
SDS-PAGE which was performed according to the
w xprocedures of Laemmli 20 , employing a slab gel
plate. The separating and stacking gels contained 14
and 10% acrylamide, respectively. The proteins were
visualized with a silver stain kit Wako Wako,
.Tokyo . The mol wt. standard comprised a mixture of
 .  .phosphorylase b 94 000 , albumin 67 000 , ovalbu-
 .  .min 43 000 , carbonic anhydrase 30 000 , trypsin
 .  .inhibitor 20 100 and a-lactalbumin 14 400 .
2.5. Ligand blotting
 .After the purified t-PAR 2 mgrml was subjected
to SDS-PAGE, the protein on the gel was electrically
transferred to nitrocellulose membrane Schleicher
. 125  . 125and Schuell . I-t-PA 10 nM or I-plasminogen
 .100 mM which had been iodinated by IODO-GEN
was reacted with the membrane in phosphate buffered
 .saline PBS in the presence or absence of 100-fold
excess unlabeled t-PA or plasminogen in PBS con-
taining 3% BSA in the presence or absence of an
excess amount of unlabeled t-PA at room temperature
for 2 hr. After the membrane was rinsed in the buffer,
it was subjected to radioautography.
2.6. Complex formation of purified t-PAR and t-PA
To examine the capacity of the purified t-PAR to
form 90 kDa complex with t-PA, the purified protein
 . 125  .100 nM was incubated with I-t-PA 25 nM at
48C for 90 min followed by the addition of 5 mM
DSS at room temperature for 30 min to cross-link
w xthese two molecules 16 . The reaction mixture was
analyzed by SDS-PAGE followed by radioautogra-
phy. Other radiolabeled ligand 125I-plasminogen, 125I-
u-PA or 125I-BSA were used to examine the cross-lin-
king specificity of the purified t-PAR.
2.7. Preparation of t-PAR-coated wells
To immobilize the purified t-PAR onto the plastic
 .well 96-well multi plate, Sumitomo Bakelite, Osaka ,
the various concentrations of t-PAR solution in coat-
ing buffer containing 0.16% Na CO , 0.3% NaHCO ,2 3 3
 .and 0.01% thimerosal pH 9.6 , were added to each
well and incubated at 48C overnight. Each well was
checked for the amount of coated protein by Cu-Folin
method, and the immobilized t-PAR of 0.8, 1.6, 3.3,
6.5, and 13 ngrwell were obtained. After the excess
 .amount of t-PA 700 ngrml, 50 ml was incubated
with each well at 48C or 90 min and then washed, the
t-PA protein which bound to each t-PAR-immobi-
lized well was measured. BSA-coated wells 0.675,
.1.35, 2.7, 5.4, and 10.7 ngrwell or nude wells were
used for the control of the experiments.
2.8. Kinetic analysis
To determine the optimal condition for the en-
hancement of t-PA activity in the presence of soluble
form of t-PAR, the plasminogen activation by t-PA
 .with plasminogen 20 mgrml, 20 ml and chro-
mogenic substrate, D-valyl-leucyl-lysine-p-nitro-
 .  . anilide S-2251 Kabi Vitrum AB, Stockholm 2
.mM, 80 ml was measured by varying molar ratio of
t-PA to t-PAR t-PARrt-PA, 0.0625, 0.125, 0.25,
.0.5, 1, 2, 4, 8 and 16 or that of t-PA to BSA
 .0.0625-16 . When t-PA was interacted with 4-fold
excess mole of t-PAR, the plasminogen activation by
t-PA was found to increase maximally. Therefore, the
kinetic analysis was performed by reacting the fixed
 .concentrations of t-PA 22 ngrml, 50 ml and t-PAR
 .25 ngrml, 50 ml with varying concentration of
 .plasminogen 1.25, 2.5, 5, 10 and 20 mgrml, 20 ml
 .and S-2251 2 mM, 50 ml . Since the binding of t-PA
to the immobilized t-PAR with 0.8-13 ngrwell was
dose-dependent of the coated protein and saturable,
the well with 6.5 ng t-PARrwell was used for the
kinetic analysis of plasminogen activation by t-PA
bound on the immobilized t-PAR with varying con-
centration of plasminogen 1.25, 2.5, 5, 10 and 20
.  .mgrml, 20 ml and S-2251 2 mM, 80 ml . The same
amount of free t-PA as immobilized t-PAR-bound
 .t-PA 22.8 ng was subjected to the assay as the
control. The results were analyzed by Lineweaver-
Burk plots to obtain the kinetic constants, K andm
k .cat
Binding of plasminogen to immobilized t-PAR
was also examined by adding plasminogen 20
.  .mgrml, 20 ml to t-PAR-coated well 6.5 ngrwell
at 48C for 90 min. After washing the well with PBS,
plasminogen activation was evaluated by reacting
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 .  .t-PA 22 ngrml, 50 ml and S-2251 2 mM, 100 ml
on the well.
Activities were determined as the increase in ab-
sorbance at 405 nm with a microplate reader MTP-120
 .Corona Electric, Katsuda .
2.9. Effect of monoclonal antibodies to annexin II on
the interaction of t-PA and t-PAR
Monoclonal antibodies to annexin II 200 mgrml,
.  .50 ml or non-immune IgG 196 mgrml, 50 ml
 .were mixed with t-PA 22 ngrml, 50 ml , plasmino-
 .  .gen 20 mgrml, 20 ml and S-2251 2 mM, 80 ml
to examine the effects of these antibodies on the
activation of plasminogen by t-PA in the presence of
 .soluble t-PAR 25 ngrml, 50 ml . In addition, fol-
 .lowing incubation of t-PA 400 ngrml, 50 ml in the
 . t-PAR-coated 6.25 ngrwell or BSA-coated 10.7
.ngrwell wells in the presence or absence of the
antibodies at 48C for 90 min, each well was washed
with PBS and then subjected to amidolytic assay with
 . plasminogen 20 mgrml, 20 ml and S-2251 2 mM,
.80 ml .
3. Results
3.1. Purification of 20 kDa protein from endothelial
cells
Endothelial cells were lyzed in the buffer consist-
 .ing of 10 mM TrisrHCl pH 7.5 containing 0.5 M
NaCl, 1 mM PMSF, 100 KIErml aprotinin and 1%
Tween 80. After insoluble cell debri had been re-
moved by centrifugation, the crude cell extract was
subjected to gel filtration with a TSK-3000SW col-
 .umn in HPLC system Fig. 1A . Low mol wt. protein
 .fractions 10–50 kDa with t-PA binding activities
 .were pooled from the elution profile Fig. 2, lane 2 .
For further purification, the low molecular weight
protein fraction was concentrated 100-fold and ap-
plied to a reversed phase column C8. The reversed
phase separation was performed with a linear gradi-
 .ent of acetonitrile in HPLC system Fig. 1B , and the
first peak fraction which was eluted at a concentra-
tion of 33% acetonitrile was identified as the single
 .20 kDa protein by SDS-PAGE Fig. 2, lane 3 . The
peak fraction was lyophilized and solubilized in 100
Fig. 1. Purification of t-PAR by gel filtration following by
reversed phase separation. Crude cell extract from HUVEC was
first subjected to gel filtration by TSK-3000SW column in HPLC
 .system A . The partially purified t-PAR which was pooled as the
low molecular weight proteins was then applied to reversed phase
 . column C8 and eluted by a linear gradient of acetonitrile max.
.70% acetonitrile in 0.1% trifluoroacetate in HPLC controlled by
 .SMART system B . The first peak with retention time at 23 min
exhibited the t-PA binding properties. The first peak obtained by
the above purification procedures was pooled and lyophilized by
Speed Vac to remove the solvent.
 .mM TrisrHCl pH 7.5 buffer as the final material.
125I-t-PA specifically bound to the purified material
 .lane 4 and the binding was inhibited in the presence
 . 125of excess unlabeled t-PA lane 5 . I-plasminogen
 .did not bind to the purified material lane 6 . Cross-
linking experiments revealed that 125I-t-PA bound to
the purified t-PAR which was observed as a complex
 . 125with mol wt. of 90 kDa lane 7 . However, I-
plasminogen failed to form a complex with the puri-
 . 125 125fied t-PAR lane 8 . Neither I-u-PA nor I-BSA
 .cross-linked with the t-PAR data, not shoum . About
2.2 mg of the protein was totally recovered from
1.0=109 cells by these purification procedures.
3.2. Assay of plasminogen acti˝ation by t-PA in the
presence of soluble t-PAR
Plasminogen activation by t-PA was measured in
the presence and absence of soluble t-PAR. When
t-PA was incubated with increasing concentrations of
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Fig. 2. SDS-PAGE in each step of purification and ligand blot.
t-PAR in each step of purification procedure was checked by
SDS-PAGErsilver stain. The analytical SDS-PAGE was per-
formed under non-reduced conditions. M, marker proteins with
molecular weight masses in kilodaltons indicated on the left; lane
1, crude extract from cells; lane 2, low molecular weight proteins
from gel filtration; lane 3, the first peak fraction by reversed
 . 125phase separation purified t-PAR ; lane 4, I-t-PA ligand blot to
the purified t-PAR; lane 5, 125I-t-PA ligand blot in the presence
of 100-fold excess unlabeled t-PA; lane 6, 125I-plasminogen
ligand blot to the purified t-PAR; lane 7, autoradiography of
125I-t-PA complexed with the purified t-PAR which was chemi-
cally cross-linked prior to SDS-PAGE; lane 8, autoradiography of
125I-plasminogen which was incubated with the purified t-PAR in
the presence of DSS prior to SDS-PAGE.
the purified t-PAR in the presence of sufficient
amount of plasminogen, plasminogen activation was
significantly enhanced in a dose-dependent manner of
t-PAR reaching the maximal enhancement of about
12-fold compared with that of t-PA with BSA instead
 .of t-PAR Fig. 3 . The maximal enhancement of
plasminogen activation was observed when t-PA was
interacted at least with 4-fold excess t-PAR. As a
control for t-PAR, BSA was added to the reaction
mixture with plasminogen and t-PA. BSA revealed
little or no increase in plasminogen activation activity
at any concentration of t-PA examined. Thus, the
enhanced plasminogen activation of t-PA by t-PAR
was specific, suggesting that t-PAR could modulate
the plasminogen activation activity of t-PA.
3.3. Assay of plasminogen acti˝ation by t-PA bound
to immobilized t-PAR
The effect on plasminogen activation of t-PA bound
to immobilized t-PAR was examined. After an ecxess
amount of t-PA was incubated on various amount of
immobilized t-PAR, plasminogen activation was ex-
pressed and increased in a dose-dependent manner of
the coated protein, indicating that t-PA could bind to
the immobilized receptor and exhibit its enzymatic
 .activity Fig. 4A . The t-PAR-dependent plasminogen
activation by t-PA was further demonstrated by the
 .saturable binding of t-PA Fig. 4B . Plasminogen
activation activity was saturable by t-PA which was
added with over 25 ngr50 mlrwell on 6.5 ng t-
PAR-coated well, and about 22 ng t-PA protein was
recovered from the well. Based on their molecular
 .weights i.e., t-PA as 70 kDa and t-PAR as 20 kDa ,
0.314 pmol t-PA could maximally bound to 0.325
pmol t-PAR. Thus, t-PA binds t-PAR with stoichi-
metrically 1:1 under these concentrations of immobi-
lized t-PAR.
In contrast to the marked plasminogen activation,
Fig. 3. Plasminogen activation activity by t-PA in the presence or
absence of soluble t-PAR. Plasminogen activation activity by
t-PA in the presence of soluble t-PAR was evaluated by varying
the molar ratio between t-PA and t-PAR t-PARrt-PAs1r16-
.  .  .16 . t-PA 22 ngrml, 50 ml v was incubated with purified
 .t-PAR solubilized in TrisrHCl buffer 3.92–100 ngrml, 50 ml
 .  .or BSA 1.15–295 ngrml, 50 ml ‘ in 96-well microtiter plate
 . by adding plasminogen 20 mgrml, 20 ml and S-2251 2 mM,
.80 ml . The plasmin generation was measured at 378C for 180
min and indicated as the increase in absorbance at 405 nm.
Values are expressed as the mean value"SD in triplicate mea-
surements.
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only a slight plasminogen activation was detected
when t-PA was added to immobilized BSA. Non-
specific binding of t-PA to the nude well was about
18% of the maximal binding of t-PA to the immobi-
lized t-PAR. Furthermore, binding of plasminogen to
immobilized t-PAR was investigated by reacting an
excess amount of plasminogen with immobilized t-
PAR or immobilized BSA. After incubating plas-
minogen with these wells, it was examined whether
plasminogen could bind to these wells by adding
t-PA and S-2251. However, no significant plasmino-
gen activation was observed under these conditions.
The above results indicate that t-PA bound specifi-
cally to immobilized t-PAR, and that the t-PA bound
to t-PAR expressed an effective plasminogen activa-
tion activity, while plasminogen did not selectively
bind to immobilized t-PAR.
3.4. Kinetic analysis of t-PA in the presence of t-PAR
The maximal enhancement of plasminogen activa-
tion was obtained when t-PA was interacted with
 .4-fold excess soluble t-PAR Fig. 3 . Therefore, ki-
netic analysis for plasminogen activation by t-PA 0.3
. nM, 50 ml in the presence of soluble t-PAR 1.2
.  .nM, 50 ml or BSA 1.2 nM, 50 ml was performed
with varying concentration of plasminogen 16.3–250
.  .nM, 20 ml Fig. 5A . K decreaced to 23% and km cat
increased to 340%, resulting in a 34-fold enhance-
ment of enzymatic efficeincy for plasminogen activa-
 .tion Table 1 . The kinetic parameters of t-PA with-
out any protein were almost the same as those with
 .BSA data, not shown .
After t-PA bound on the immobilized t-PAR 0.3
.pmolrwell , plasminogen activation activity of the
Fig. 4. Activation of plasminogen by t-PAR-bound t-PA. t-PA was incubated with various amounts of purified t-PAR which had been
 .  .  .immobilized to the well of microtiter plate A . After the t-PAR-coated wells were incubated with excess t-PA 700 ngrml, 50 ml v at
 .  .48C for 90 min, the wells were washed and added with plasminogen 20 mgrml, 20 ml and S-2251 2 mM, 80 ml . BSA-coated wells
 .  .0.68, 1.35, 2.7, 5.4 and 10.7 ngrwell were incubated with t-PA ‘ followed by washing of the well and addition of plasminogen and
 .  .  .S-2251 as described above. Immobilized t-PAR 6.5 ngrwell was also incubated with plasminogen 20 mgrml, 50 ml ’ which was
 .  .  .then washed and added with t-PA 700 ngrml, 50 ml and S-2251 2 mM, 100 ml . Immobilized BSA 10.7 ngrwell was also incubated
 .with plasminogen ^ followed by washing of the well and addition of t-PA and S-2251. The same protocols were performed using
 .protein-non-coated well as a control immobilized protein, 0 ngrwell . The immobilized t-PAR was added with increasing concentration
 .  .  .of t-PA B . Plasminogen activation activity was measured as described above on immobilized t-PAR 6.5 ngrwell v , immobilized
 .  .  .BSA 10.7 ngrwell ‘ , or nude well ^ . The activity was determined as the increase in absorbance at 405 nm. Values are expressed
as the mean value"SD in triplicate measurements.
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 .  .Fig. 5. Effect of soluble A and immobilized B t-PAR on
kinetics of plasminogen activation by t-PA. Plasminogen activa-
 .tion activity of t-PA 22 ngrml, 50 ml which was incubated
 .with purified t-PAR 25 ngrml, 50 ml and that of t-PA which
 .saturablly bound on immobilized t-PAR 6.25 ngrwell were
measured by varying concentrations of plasminogen as described
in Section 2. The initial rates of plasminogen activation of t-PA
 .  .  .A in the presence of soluble t-PAR v or BSA ‘ , and those
 .  .  .of t-PA B bound on immobilized t-PAR v or in solution ‘
were plotted against plasminogen concentration as Lineweaver-
Burk plots.
 .  .t-PA 0.3 pmol was efficiently expressed Fig. 5B
where K decreased to 44% and k increased tom cat
856%, resulting in a 90-fold enhancement. These
Table 1
Kinetic parameters of t-PA with free t-PAR and t-PA bound to
immobilized t-PAR
y1 .K k s k rK Foldm cat cat m
y1 y1 a .  .nM s PnM increase
y2 y4Control-1 204.9 5.34=10 2.61=10 1
y2 y4Free t-PAR 47.4 41.7=10 88.8=10 33.8
y2 y4Control-2 203.1 1.47=10 0.72=10 1
y2 y4Immobolized 89.2 57.7=10 64.7=10 89.8
t-PAR
Plasminogen activation activity by t-PA was determined by the
 .amidolysis of S-2251 in the presence of BSA Control-1 or free
t-PAR with varying concentration of plasminogen as described in
Section 2. Activity of the same amount of t-PA in the fluid phase
 .as the immobilized t-PAR-bound t-PA was measured Control-2
 .and compared with that on the immobilized t-PAR 6.6 ngrwell .
a The enhancement of t-PA activity was expressed as a fold-in-
 .crease in enzyme efficiency k rK which was comparedcat m
with each control.
results indicate that the enzymatic activity for plas-
minogen activation by immobilized t-PAR-bound
t-PA was further promoted than that in the presence
 .of soluble t-PAR Table 1 .
From these results, it was concluded that 20 kDa
protein is a specific receptor for t-PA and not for
plasminogen, and that t-PAR functions as an en-
hancer of t-PA activity by interacting or binding with
t-PA molecule.
3.5. Characterization of t-PAR
Since t-PAR of mol wt. 40 kDa from the placenta
or endothelial cells was reported to bind to plasmino-
w xgen as well as t-PA 17 and the molecule was
w xidentified as annexin II 12 , we examined whether or
not t-PAR of mol wt. 20 kDa was related to annexin
II. As shown in Fig. 6, the effect of three kinds of
mouse monoclonal antibodies to annexin II on plas-
minogen activation by t-PA in the presence of t-PAR
Fig. 6. Effect of monoclonal antibodies to annexin II on soluble
t-PAR-induced enhancement of plasminogen activation by t-PA
and on t-PA binding to the immobilized t-PAR. Plasminogen
 .activation activity of t-PA in the presence lanes 2 to 6 or
 .  .absence lane 1 of soluble t-PAR black bar was measured in
the optimal condition as described in Fig. 3, with monoclonal
 .  .antibodies 200 mgrml, 50 ml to annexin II lane 3 , specific to
 .  .its light chain lane 4 and heavy chain lane 5 or non-immune
 .  .IgG 196 mgrml, 50 ml lane 6 . Plasminogen activation activ-
 .ity of t-PA after binding to immobilized proteins hatched bar
was measured as described in Fig. 4 with BSA-coated 10.8
.  .  .  .ngrwell lane 1 or t-PAR-coated 6.5 ngrwell lanes 2 to 6
wells in the presence of three kinds of anti-annexin II antibodies
 .  .described above 200 mgrml, 50 ml lanes 3, 4 and 5 or
 .  .non-immune IgG 196 mgrml, 50 ml lane 6 . Each bar ex-
presses as the mean value"SD in triplicate measurements.
( )H. Fukao et al.rBiochimica et Biophysica Acta 1356 1997 111–120118
was examined. In this set of experiment, soluble
t-PAR showed about a 10-fold enhancement of the
plasminogen activation by t-PA lanes 1 and 2, black
.bars . To examine whether or not the purified t-PAR
was identical with annexin II or annexin II-related
molecules, a panel of monoclonal antibodies to an-
nexin II were employed. When each antibody was
added to the reaction mixture of t-PAR, t-PA and
plasminogen, the plasminogen activation was not sig-
 .nificantly changed lanes 3 to 5, black bars as well
as that in the presence of non-immune IgG lane 6,
.black bar . Furthermore, when t-PA was added to
t-PAR-coated wells in the presence or absence of
 .anti-annexin II antibodies Fig. 6 , plasminogen acti-
vation activity by t-PA on immobilized t-PAR was
not significantly changed in the presence of anti-an-
 .nexin II antibodies lanes 3 to 5, hatched bars or
 .non-immune IgG lane 6, hatched bar , suggesting
that the immobilized t-PAR is not composed of such
a protein as annexin II or annexin II-related molecule.
On the other hand, when t-PA was added to the
t-PAR-coated well without these antibodies, about a
6-fold increase in plasminogen activation was ob-
 .served lane 2, hatched bar as compared to the
plasminogen activation in the BSA-coated well lane
.1, hatched bar . In addition, these antibodies did not
 .alter the activities of t-PA data, not shown . These
results suggest that several epitopes which are recog-
nized by a panel of anti-annexin II monoclonal anti-
bodies are not involved in the t-PAR for the enhance-
ment of plasminogen activation of t-PA.
4. Discussion
The present data support the idea that the cellular
fibrinolytic system is regulated by the expression of
 .t-PA receptor t-PAR in vascular endothelial cells. A
major part of the binding of t-PA occurs with PAI-1
w x w xon either the cell surface 21 or the ECM 4 result-
ing in inhibition of the plasminogen activation by
t-PA. On the other hand, the binding of t-PA to the
cell surface may enhance plasminogen activation
which affords the endothelial cells with antithrom-
botic properties. The specific receptor for u-PA, u-
PAR, has been well characterized, and a pericellular
proteolytic system mediated by u-PA has been
demonstrated. u-PA immobilized on u-PAR is pre-
w xdominantly involved in cell migration 22 , tissue
w xremodeling 23 , and cell invasion, tissue destruction
w xand the metastasis of cancer cells 8–10 . Although
w xendothelial cells also express u-PAR 11 , the func-
tion of the u-PAR in the regulation of intravascular
fibrinolysis remains to be identified. Since t-PA is a
major activator of plasminogen in the intravascular
fibrinolytic system, the event of specific binding of
t-PA to endothelilal cells may play a crucial role in
the expression of fibrinolytic activity on these cells.
Our previous findings have indicated that the bind-
ing of t-PA to endothelial cells was specific and
saturable both in suspended cells and in monolayered
cells in the presence of anti-PAI-1 IgG. Further, our
previous experiments demonstrated that t-PA bound
to endothelial cells was recovered as 90 kDa complex
from the cell lysates, and that in ligand blot analysis
t-PA bound to mol wt. 20 kDa protein which did not
w xreact with plasminogen 15 .
In the present study, mol wt. 20 kDa protein was
purified from human umbilical vein endothelial cells.
Detailed analysis revealed that it was quite different
from the t-PAR reported previously in terms of
w xmolecular weight 12,17 and reactivity with plas-
w xminogen 12,14 .
The binding site of the t-PA molecule to t-PAR
was examined. A previous study indicated that the
interaction of t-PA with t-PAR was mediated by
lysine binding sites, since 5 mM 6-aminohexanoic
acid inhibited the binding of radiolabeled t-PA to 20
w xkDa protein 16 . In the present study, t-PA bound to
immobilized t-PAR which represents a model system
of the cell surface, and the t-PA on the t-PAR
enhanced its plasminogen activation activity Fig. 4
.and Table 1 . Since t-PA in the presence of soluble
t-PAR enhances its plasminogen activation activity
 .Fig. 3 , it appears that t-PA may bind to soluble
t-PAR in a manner similar to fibrin- or fibrinogen-de-
w xgradation products 24 . These observations suggest
that the binding region of t-PA to t-PAR is not
involved in the catalytic domain of t-PA, but possibly
kringle domains containing lysine binding sites. Since
t-PA formed 90 kDa complex with the purified t-PAR
 .Fig. 2, lane 7 , it was suggested that t-PA bound to
the immobilized t-PAR with stoichimetrically 1:1 and
expressed its enzymatic activity more effieciently
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than t-PA in the fluid phase. In contrast to the
immobilized t-PAR, t-PA with 4-fold excess soluble
t-PAR exhibited the maximal enhancement of plas-
minogen activation, indicating that the efficient inter-
action andror binding between the two molecules
could proceed, when the t-PAR exists in its soluble
form. The t-PA receptor molecule of mol wt. 40 kDa
which was isolated from endothelial cells and identi-
fied as annexin II, exhibits a capacity to interact with
plasminogen. However, t-PA and plasminogen do not
compete in their binding to the t-PAR, implying that
t-PA and plasminogen bind to distinct sites in the
w xt-PAR molecule 12 . In contrast, t-PA and plasmino-
gen do compete with each other in their binding in a
variety of cell lines including endothelial cells, and
one of the candidates for plasminogen receptor, a-en-
olase, also interacts with both plasminogen and t-PA,
suggesting that t-PA and plasminogen share a com-
w xmon binding site on the cells 14 . These receptors
thus have a dual function for the binding of the
fibrinolytic factors, t-PA and plasminogen. On the
other hand, t-PAR which is purified as a mol wt. 20
kDa protein reacts only with t-PA and not with
 .plasminogen Fig. 2 lanes 4, 7 and 8 . In addition, if
plasminogen could bind to the immobilized t-PAR
 .with low affinity as reported by Hajjar 0.114 mM
w x  . w x17 or Miles 2.1"1.3 mM 14 , the concentration
 .of plasminogen added 0.25 mM was considered
almost saturable on the immobilized t-PAR so that a
significant plasminogen activation would be expected
after adding t-PA. However, no significant plasmino-
gen activation was observed, which also indicates
that plasminogen did not bind to the 20 kDa-receptor.
Though plasminogen competes with t-PA for binding
w xto endothelial cells as we previously reported 16
w xand as described by other groups 12,14 , we did not
detect any complex formation between plasminogen
and the t-PAR on endothelial cells, suggesting that
plasminogen did only interfere the binding of t-PA to
the t-PAR but did not bind tightly to the t-PAR. The
isolated t-PAR also does not bind plasminogen.
Therefore, it seems that if plasminogen can interact
with the t-PAR, the binding of plasminogen is ex-
trememly lower than that of t-PA, resulting in no
complex formation between t-PAR and plasminogen
even after cross-linking by DSS. Though the low
affinity binding of plasminogen to endothelial cells
have been demonstrated as described above, it re-
mains unclear how plasminogen interacts with its
 .binding site s and whether plasminogen forms such
 .a stable complex with its binding site s as can be
observed by SDS-PAGE.
A single ligand-single receptor system may bring
about a specific cellular response by binding of t-PA
to t-PAR, although it remains to be determined what
kind of signal transduction is induced in endothelial
cells by the binding of t-PA to t-PAR.
The t-PAR may function as an enhancing factor of
t-PA on the surface of endothelial cells, since exoge-
nously added t-PA exhibited much enhanced plas-
minogen activation activity in the presence of HU-
 .VEC data, not shown . Furthermore, t-PA-treated
HUVEC showed a significant plasminogen activation
indicating that t-PA bound on the cell surface ex-
presses its functional activity, though the inhibition
ratio by PAI-1 remains to be studied. Although the
authors did not substantially identify the existence of
annexin II in HUVEC, anti-annexin II monoclonal
antibodies employed in this study partially reduced
plasminogen activation by t-PA on HUVEC, suggest-
ing that annexin II may be involved in the expression
of t-PA-mediated plasminogen activation on the cell
surface. However, excess amount of authentic an-
nexin II derived from fibroblasts did not affect the
increase of t-PA activity in the presence of purified
 .t-PAR data, not shown .
Therefore, based on our findings that a panel of
monoclonal antibodies with different epitops to an-
nexin II did not interfere the interaction between t-PA
and the 20 kDa-t-PAR and its enhancing potential for
 .plasminogen activation by t-PA Fig. 6 and that
anti-a-enolase IgG did not cross react with the t-PAR
w xas previously reported 16 , it is concluded that this
molecule is substantially quite different from annexin
II and that this novel protein functions as a specific
receptor for t-PA and an enhancer of t-PA activity on
the surface of endothelial cells.
The possible physiological significance of t-PAR
 .may be summarized as follows: 1 t-PA is assembled
and concentrated on the surface of endothelial cells
 .by t-PAR; 2 the t-PA on t-PAR expresses its enzy-
matic activity efficiently, leading to focal plasmino-
 .gen activation; and 3 these elements afford the
endothelial cells with an effective pericellular fibri-
nolytic activity which contributes to the antithrom-
botic properties of the endothelium.
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